|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,848.00 GBX | -1.73% |
|
-2.27% | +1.29% |
| 15/01 | Stocks in green as US manufacturing surprises | AN |
| 15/01 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| Capitalization | 7.41TCr 9.93TCr 8.55TCr 7.97TCr 14TCr 8,97000Cr 15TCr 92TCr 36TCr 4,28800Cr 37TCr 36TCr 15,73200Cr | P/E ratio 2025 * |
14.4x | P/E ratio 2026 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 8.83TCr 12TCr 10TCr 9.49TCr 16TCr 10,68000Cr 18TCr 1,09000Cr 43TCr 5,10600Cr 44TCr 43TCr 18,73200Cr | EV / Sales 2025 * |
2.71x | EV / Sales 2026 * | 2.51x |
| Free-Float |
94.52% | Yield 2025 * |
3.52% | Yield 2026 * | 3.79% |
Last Transcript: GSK plc
| 1 day | -1.73% | ||
| 1 week | -2.27% | ||
| Current month | +1.29% | ||
| 1 month | +0.79% | ||
| 3 months | +13.51% | ||
| 6 months | +31.76% | ||
| Current year | +1.29% |
| 1 week | 1,833 |  | 1,902.5 |
| 1 month | 1,793 | | 2,057.7 |
| Current year | 1,799.84 | | 1,909.73 |
| 1 year | 1,242.5 | | 2,057.7 |
| 3 years | 1,242.5 | | 2,057.7 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 01/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.50% | 3.15% | 26 M€ | |
| +0.00% | 2.97% | 62 M€ | |
| +32.06% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.73% | -2.27% | +39.21% | +28.82% | 9.93TCr | |
| -3.76% | -4.81% | +38.33% | +185.65% | 92TCr | |
| +0.47% | +6.72% | +51.46% | +26.60% | 53TCr | |
| -2.32% | -3.29% | +26.50% | +41.11% | 38TCr | |
| +0.46% | +1.86% | +30.01% | +18.51% | 37TCr | |
| -2.23% | -1.06% | +31.72% | +20.33% | 29TCr | |
| -1.36% | +0.63% | +26.39% | +35.48% | 27TCr | |
| -0.04% | -0.02% | +10.87% | -1.14% | 28TCr | |
| -3.45% | -1.39% | -39.64% | -22.02% | 25TCr | |
| +0.32% | -0.02% | +22.72% | +21.46% | 18TCr | |
| Average | -1.36% | -0.37% | +23.76% | +35.48% | 35.74TCr | |
| Weighted average by Cap. | -1.67% | -0.61% | +28.33% | +62.89% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.26TCr 4.36TCr 3.76TCr 3.5TCr 6.06TCr 3,94000Cr 6.5TCr 40TCr 16TCr 1,88400Cr 16TCr 16TCr 6,91000Cr | 3.42TCr 4.57TCr 3.94TCr 3.67TCr 6.35TCr 4,13300Cr 6.82TCr 42TCr 17TCr 1,97600Cr 17TCr 17TCr 7,24800Cr |
| Net income | 514.82Cr 689.35Cr 593.8Cr 553.38Cr 957.75Cr 62TCr 1.03TCr 6.36TCr 2.5TCr 30TCr 2.58TCr 2.53TCr 1,09200Cr | 646.53Cr 865.7Cr 745.72Cr 694.95Cr 1.2TCr 78TCr 1.29TCr 7.98TCr 3.14TCr 37TCr 3.25TCr 3.18TCr 1,37200Cr |
| Net Debt | 1.41TCr 1.89TCr 1.63TCr 1.52TCr 2.63TCr 1,71000Cr 2.82TCr 17TCr 6.87TCr 82TCr 7.1TCr 6.95TCr 3,00000Cr | 1.16TCr 1.56TCr 1.34TCr 1.25TCr 2.17TCr 1,40900Cr 2.32TCr 14TCr 5.66TCr 67TCr 5.85TCr 5.73TCr 2,47100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 1,848.00 p | -1.73% | 49,81,120 |
| 14/26/14 | 1,880.50 p | +1.21% | 65,53,009 |
| 13/26/13 | 1,858.00 p | -1.01% | 57,89,940 |
| 12/26/12 | 1,877.00 p | -0.48% | 56,48,904 |
| 09/26/09 | 1,886.00 p | -0.26% | 63,49,278 |
Delayed Quote London S.E., January 15, 2026 at 10:05 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition